MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/art.70000

Медицинская библиотека · Arthritis & rheumatology (Hoboken, N.J.) · 2026

Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability.

Flatman Leah K, Bernatsky Sasha, St-Pierre Yvan, Beauchamp Marie-Eve, Malhamé Isabelle, Bérard Anick, Vinet Évelyne

СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability.

METHODS

Using MarketScan (2011-2021), we identified offspring born to mothers with chronic inflammatory diseases. TNFi exposure was defined as at least one filled prescription during pregnancy, further subdivided by trimesters and placental transfer. The event of interest was the time to first hospitalization with infection in the offspring's first year of life. We estimated associations between TNFi exposure and infection risk using multivariable Cox proportional hazards models, adjusting for maternal demographics, disease type, comorbidities, pregnancy complications, and drug exposure.

RESULTS

We identified 56,866 offspring; 3,711 (6.5%) were exposed to TNFi during pregnancy. Overall, the association of TNFi exposure with the risk of serious infections vs unexposed offspring was not statistically significant (hazard ratio [HR] 0.85; 95% confidence interval [CI] 0.68-1.07). However, offspring exposed during the third trimester had a 70% higher risk of serious infections than those exposed only in the first and/or second trimesters (HR 1.70; 95% CI 0.96-3.01). Additionally, we observed an increased risk with exposure to any TNFi with high placental transfer ability (infliximab, adalimumab, golimumab) overall (HR 1.49; 95% CI 0.83-2.69) and during the third trimester (HR 1.30, 95% 0.65-2.61), compared to only low placental transfer TNFi (certolizumab, etanercept), though both HR were not statistically significant.

CONCLUSION

Overall, TNFi exposure was not associated with serious infections; exploratory signals by timing and placental transfer were imprecise and require confirmation.

Для цитирования: Flatman Leah K, Bernatsky Sasha, St-Pierre Yvan, Beauchamp Marie-Eve, Malhamé Isabelle, Bérard Anick, Vinet Évelyne. Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability.. Arthritis & rheumatology (Hoboken, N.J.). 2026. DOI: 10.1002/art.70000.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.